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Summary
 
Mice immunized with optimal doses of autologous tumor–derived gp96 resist a challenge with
the tumor that was the source of gp96. Immunization with quantities of gp96 5–10 times larger
than the optimal dose does not elicit tumor immunity. This lack of effect is shown to be an ac-
tive, antigen-specific effect, in that immunization with high doses of tumor-derived gp96, but
not normal tissue–derived gp96, downregulates the antitumor immune response. Furthermore,
immunization with fractionated doses of gp96 elicits the same kind and level of response as
elicited by a single dose equivalent to the total of the fractionated doses. This is true of the tu-
mor-protective doses as well as the high downregulatory doses of gp96. The downregulatory
activity can be adoptively transferred by CD4
 
1
 
 but not CD8
 
1
 
 T lymphocytes from mice im-
munized with high doses of gp96. These observations indicate that immunization with gp96
induces a highly regulated immune response that, depending upon the conditions of immuniza-
tion, results in tumor immunity or downregulation.
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I
 
mmunization of mice with preparations of heat shock
proteins (HSPs)
 
1
 
 isolated from tumors or virus-infected
cells has been shown to elicit specific protective immunity
against the tumor or the virus-infected cells used as the
source of the HSP. This phenomenon has been shown to be
general, in that specific immunogenicity of tumor-derived
HSP preparations has been demonstrated in the case of hepa-
tomas (1), fibrosarcomas (2–8), lung carcinoma (9), prostate
cancer (10), spindle cell carcinoma (9), colon carcinoma (9),
and melanoma (9) in mice and rats of different haplotypes.
These tumors include chemically induced (1–8, 10), UV-
induced (11), and spontaneous tumors (9), and efficacy has
been demonstrated in prophylactic (1–8, 10, 11) as well as
therapeutic (9) models. In the case of viral models, HSP
preparations from cognate cells have been shown to elicit vi-
rus-specific cellular immune response against influenza virus
(12), SV40 (13), vesicular stomatitis virus (14), and lympho-
cytic choriomeningitis virus (15). HSP preparations from
cells transfected with model antigens such as 
 
b
 
-galactosidase
have been shown to elicit antigen-specific CTLs against
 
b
 
-galactosidase (16). The structural basis of this broad phe-
nomenon lies in the fact that HSP preparations isolated from
a given cell are associated with the range of peptides, includ-
ing self and antigenic peptides, generated within that cell and
that HSP–peptide complexes are highly immunogenic (17).
In earlier studies demonstrating the specific immuno-
genicity of the cognate tumor–derived HSP–gp96 (2), it was
noted that the activity of gp96 was dose-restricted, i.e.,
very low doses of gp96 did not immunize, higher doses im-
munized effectively, and even higher doses failed to immu-
nize at all. Although trivial reasons for this observation (i.e.,
high protein quantity, salts, etc.) were ruled out, this inter-
esting and important phenomenon has not been examined
since. Studies reported here explore that observation and
shed light on the dual nature (immunogenic and downreg-
ulatory) of immunogenicity of gp96–peptide complexes.
These results have implications for downregulation of anti-
gen-specific T cell immune response.
 
Materials and Methods
 
Mice.
 
Female BALB/cJ mice (6–8 wk of age) bought from
The Jackson Laboratory were maintained at the Fordham Uni-
versity (Bronx, NY) vivarium.
 
Purification of gp96.
 
Meth A cells, grown in ascites, and livers
from naive BALB/cJ mice served as the source of gp96. Purifica-
tion of gp96 was performed as described earlier (2).
 
Immunization.
 
Two doses of gp96 were administered 1 wk
apart and mice were challenged with tumor cells 7 d after the last
immunization. Injections were performed using a 1-cm
 
3
 
 insulin
syringe (Becton Dickinson) in a volume of 200 
 
m
 
l. Subcutaneous
injections were administered under the loose skin fold in the cer-
vical region, dorsally, and intradermal injections were given in
the skin on the ventral aspect of the trunk. During intradermal
injection, care was taken to ensure that the inoculum was in the
 
1
 
Abbreviation used in this paper: 
 
HSPs,
 
 
 
heat shock proteins. 
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intradermal compartment without extravasation into the subcuta-
neous area. This estimation was made by the presence of a raised
bleb confirming intradermal inoculation. Intravenous immuniza-
tion was given retro-orbitally into the venous plexus. Oral im-
munization was administered by feeding the mice 200 
 
m
 
l of gp96
solution using the nozzle of a syringe. Intramuscular vaccination
was performed in the muscle of the thigh. gp96 was injected in-
traperitoneally by inserting the needle subcutaneously for a length
of 2 mm and then turning at right angles to the long axis of the
body to penetrate the muscle and peritoneum. After injecting
the requisite amount of inoculum, the needle was withdrawn in
the same order. This method ensured that there was no extrava-
sation of the inoculum from the peritoneal cavity, as the entry
points in the skin and the peritoneum did not line up.
 
Tumor Rejection Assays.
 
Meth A and CMS5 lines, derived
from antigenically distinct, chemically induced murine sarcomas,
were used. Tumor challenges comprised 100,000 live cells (Meth A
or CMS5), administered intradermally on the shaved dorsal aspect
of the mouse. Tumor growth was recorded twice per week using
vernier calipers measuring both the longitudinal and the trans-
verse diameter. Average diameters of the two axes were plotted.
 
Isolation and Adoptive Transfer of T Cell Subsets.
 
Spleens were
harvested from donor mice and RBCs were removed by incuba-
tion of the total cells with a filtered solution containing ammonium
chloride and Tris base, pH 7.2. The residual cells were labeled with
MACS
 
®
 
 antibodies for CD4
 
1
 
 or CD8
 
1
 
 cells (Miltenyi Biotec) and
loaded onto MACS
 
®
 
 VS
 
1
 
 separation columns (Miltenyi Biotec).
After repeated washings, the cells were eluted off the columns and
counted. FACS
 
®
 
 analysis confirmed 
 
.
 
90% purity of the cells. As
control donors, cells from mice immunized with buffer and the
same age as the recipients were used. Cells were tested for 
 
.
 
95%
viability, suspended in 200 
 
m
 
l plain RPMI, and injected intrave-
nously via the retro-orbital venous plexus of recipient mice.
 
Results
 
Dose Restriction of Immunogenicity of gp96.
 
The data in
Fig. 1 show the dose-restricted nature of immunogenicity of
gp96. BALB/c mice were immunized subcutaneously with
Meth A–derived gp96 with 1, 5, 10, or 50 
 
m
 
g per injection
 
(twice, 1 wk apart) and were challenged with 100,000 Meth
A cells 1 wk after the last challenge. In accord with a previ-
ous report, immunization with 10 
 
m
 
g gp96 was effective at
eliciting tumor rejection, whereas lower (1- and 5-
 
m
 
g) and
higher (50-
 
m
 
g) doses were ineffective (Fig. 1, top). Doses
lower than 1 
 
m
 
g Meth A–derived gp96 were also tested and
found to be ineffective (data not shown). Doses between 10
and 50 
 
m
 
g were also tested in independent experiments, and
a gradual diminution of activity was observed at higher doses
in this range: immunization with 20, 30, or 50 
 
m
 
g of gp96
led to tumor take in 1/5, 3/5, and 4/5 mice, respectively.
Thus, the dose restriction was consistent, reproducible, and
titratable. In a demonstration of specificity of gp96-elicited
immunity, immunization with gp96 derived from normal
liver was found ineffective at eliciting immunity to Meth A,
and mice immunized with Meth A–derived gp96 remained
sensitive to challenges with a syngeneic and antigenically dis-
tinct fibrosarcoma CMS5 (Fig. 2).
When mice were immunized with Meth A–derived gp96
by various routes at various doses (1, 5, 10, and 50 
 
m
 
g per dose,
two doses given 1 wk apart), several novel aspects emerged
(Fig. 1). As little as 1 
 
m
 
g of gp96 administered intradermally
imparted tumor protection, whereas a minimum of 10 
 
m
 
g was
needed subcutaneously and 50 
 
m
 
g intraperitoneally to elicit
corresponding levels of protection. Thus, intradermal immuni-
zation was more efficient than subcutaneous, and subcutaneous
more efficient than the intraperitoneal route, on a per-micro-
gram basis. Immunization with any dose of gp96 by intramus-
cular, oral, or intravenous routes showed no protection from
tumor challenge (data not shown). Furthermore, although the
subcutaneous and intradermal routes were observed to vary
quite significantly, dose restriction of activity was observed in
both routes (Fig. 1). In the case of intradermal immunization,
 
,
 
1 
 
m
 
g gp96 was ineffective, 1 
 
m
 
g was the optimal dose, and 10
 
m
 
g did not elicit protective immunity; in the case of subcutane-
ous immunization, 
 
,
 
10 
 
m
 
g gp96 was ineffective, 10 
 
m
 
g was
the optimal dose, and 50 
 
m
 
g did not elicit protective immunity.
Figure 1. Dose restriction of immunoge-
nicity of tumor-derived gp96. BALB/c mice
were immunized with Meth A gp96 in the
quantities and routes indicated. Immuniza-
tions were carried out twice per week, and
the doses indicated represent the quantities
administered at each immunization. All mice
were challenged with 100,000 Meth A cells
1 wk after the last immunization. Each line
shows the kinetics of tumor growth in a sin-
gle mouse. 
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Other parameters of immunity elicited by immunization
with gp96 by various routes also showed common patterns.
Immunity elicited by all routes was exquisitely tumor spe-
cific, and mice immunized by all routes developed a mem-
ory response. Mice immunized intradermally or subcutane-
ously with Meth A–derived or liver-derived gp96 were
parked for 3 mo following the last immunization and were
challenged at the end of that period with live Meth A cells.
Meth A–derived gp96, given intradermally, intraperitoneally,
or subcutaneously, elicited specific protection from subsequent
challenge with Meth A and failed to protect from CMS5 chal-
lenge (Fig. 2). Liver-derived gp96, delivered by any route,
failed to protect from tumor challenge (Fig. 2, bottom).
 
Lack of Immunogenicity of High Doses of gp96 Is Antigen
Specific.
 
As higher than optimal doses of gp96 did not im-
munize, it was difficult to assess the antigen specificity of
this nonresponse. However, a method of testing this ques-
tion was developed based on the phenomenon of concom-
itant immunity (18). It has been observed previously that if
mice are challenged with a given tumor at one site in the
body, and if this tumor is allowed to grow, the mice show
resistance to challenge with the same tumor at another ana-
tomical site. Thus, although the animal succumbs to a tu-
mor at one location, it resists the same tumor at another lo-
cation. This phenomenon is only observed during a narrow
time window of 6–9 d after primary tumor transplantation.
North and Bursuker (18) have elegantly demonstrated that
concomitant immunity results from the fact that progres-
sively growing tumors elicit an antitumor immune re-
sponse, which gets rapidly downregulated after a certain
period. In the period before downregulation has occurred,
 
mice show systemic protective immunity to challenges
with the same tumor as used in the primary challenge but
not to other, antigenically distinct tumors (18).
In the present study, we sought to test whether prior im-
munization of mice with higher than optimal doses of
Meth A–derived or unrelated gp96 would or would not
abrogate concomitant immunity. The design of this experi-
ment is shown in Fig. 3 A. Mice were preimmunized with
gp96 in either tumor-protective doses (1 
 
m
 
g intradermal
[i.d.] or 10 
 
m
 
g s.c.) or higher doses (10 
 
m
 
g i.d. or 100 
 
m
 
g
s.c.) and subsequently challenged with live tumor cells. 8 d
after tumor challenge, the growing tumors were excised.
(As shown earlier, all mice develop tumors that grow
equally and at a consistent rate for the first 5–10 d, after
which they either regress or continue to grow depending
upon the immunizing dose.) Mice were allowed to recover
for 4–7 d after surgery and were then rechallenged with
Meth A tumor cells. The kinetics of tumor growth in each
group were monitored.
It was observed (Fig. 3 B) that mice that had been pre-
immunized with the larger doses of Meth A gp96 showed a
loss of concomitant immunity to the second tumor chal-
lenge. Previous immunization with buffer alone or with
optimal or larger doses of liver-derived gp96 did not show
abrogation of immunity. These observations were noted in
mice immunized by the subcutaneous or intradermal
routes. The results show that the larger than optimal doses
of cognate gp96 elicit an antigen-specific downregulatory
influence on immune response.
 
Downregulation of Immune Response by High Doses of gp96
Can Be Adoptively Transferred by CD4
 
1
 
 T Lymphocytes.
 
As
Figure 2. Specificity of gp96-elicited
tumor immunity, regardless of the route
of immunization. Mice were immunized
with Meth A gp96 or liver gp96 adminis-
tered intradermally, subcutaneously, or in-
traperitoneally and were challenged with
either Meth A or CMS5 sarcomas. Exper-
imental details are the same as in the Fig. 1
legend. 
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the loss of tumor immunity elicited by high doses of gp96
would appear similar to immunization with buffer, an indi-
rect assay had to be devised to measure the activity of high
doses of gp96. Mice were first immunized with doses of gp96
that elicit tumor immunity. These mice then received sera or
T cell subsets from other mice that had been previously
immunized with high doses of gp96. Preliminary analysis
suggested that a cellular and not a humoral component could
transfer downregulation (data not shown). Furthermore,
splenic T lymphocytes from mice immunized with high
doses of Meth A–derived gp96 were fractionated into CD4
 
1
 
and CD8
 
1
 
 populations as described in Materials and Meth-
ods. The lymphocytes were adoptively transferred to mice
that had been previously immunized with the effective dose
of gp96. All mice were challenged with Meth A cells, and the
kinetics of tumor growth were monitored. It was observed
(Fig. 4) that tumor immunity was abrogated in mice that
received CD4
 
1
 
 T lymphocytes from high-dose gp96–immu-
nized mice; in contrast, mice that received CD8
 
1
 
 T lympho-
cytes from the high-dose gp96–immunized group remained
protected, as did the mice that received CD4
 
1
 
 or CD8
 
1
 
T lymphocytes from buffer-immunized mice. In other con-
trol experiments, mice that received buffer or CD4
 
1
 
 or
CD8
 
1
 
 T lymphocytes from low-dose gp96–immunized mice
remained protected from tumor challenge (data not shown).
 
Immunization with Fractionated Doses of gp96 and Summation
of Response.
 
Intradermal immunization with 1 
 
m
 
g Meth A
gp96 given in divided doses at different sites (0.25 
 
m
 
g/site
in four sites, targeting different regional lymph nodes) was
found to elicit protective tumor immunity. The 0.25-
 
m
 
g
dose administered at one site only did not elicit immunity
(Fig. 5). The degree of protection conferred by immuniza-
tion with 0.25 
 
m
 
g/site at four sites was comparable to that
elicited by 1 
 
m
 
g given at a single site or as a single dose.
The higher dose of gp96 (5 
 
m
 
g i.d. at a single site), which
mediated active downregulation of immune response when
administered at one site in one large dose, also mediated
downregulation when given in four divided doses of 1.25
 
m
 
g each, intradermally, at multiple sites (Fig. 5). These ob-
servations indicate that gp96-induced immunity shows spa-
tial summation and suggest the existence of a substantial de-
gree of cross-talk between lymph nodes.
 
Discussion
 
Studies reported here indicate that immunization with
gp96 preparations elicits a complex and highly regulated
immune response, which, depending upon the route and
the quantity used for the immunization, results in antitu-
mor immune response or its downregulation. The lack of
tumor-protective responses by high doses of gp96 is not a
null event but an active process that can downregulate tu-
mor immunity elicited by immunization with a growing
tumor or by the optimal dose of the cognate gp96. This ac-
tive process includes generation of a downregulatory CD4
 
1
 
T lymphocyte population. Although there is precedent for
CD4
 
1
 
 T cell populations that can downregulate immune
response to cancers and infectious agents (19, 20), the
mechanisms through which they implement their action
have not been elucidated in the present or previous sys-
tems. This must await cloning and structural characteriza-
Figure 3. Antigen specificity
of downregulation of immune
response elicited by immuniza-
tion with high doses of gp96. (A)
The experimental plan used to
measure the effect of immuniza-
tion with gp96 on concomitant
immunity; see text for details. (B)
Immunization with high doses (10
mg i.d.) of Meth A gp96 but not
liver gp96 elicits loss of concom-
itant immunity to Meth A sar-
coma. Corresponding experi-
ments were also carried out with
subcutaneous administrations of
gp96 with similar results (data
not shown).
Figure 4. Role of CD41 T lymphocytes in mediating downregulation
of immune response. All (recipient) mice shown were immunized with 1 mg
of Meth A gp96 i.d. CD41 or CD81 T lymphocytes from mice immu-
nized with buffer or high-dose Meth A gp96 (10 mg i.d.) were adoptively
transferred (1.25 3 107 CD41 T lymphocytes/mouse; 3.7 3 106 CD81 T
lymphocytes/mouse) into the recipient mice, which were challenged
with 100,000 Meth A cells. Each line represents the kinetics of tumor
growth in a single mouse. As controls, CD41 or CD81 T lymphocytes
from mice immunized with 1 mg Meth A gp96 were also transferred into
the recipient mice; however, such transfer had no influence on the tumor
immunity in the recipient mice (data not shown). 
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tion of the downregulatory cells and the cytokines elabo-
rated by and responded to by them.
As APCs play the central role in immunogenicity of
gp96 preparations (5), the log scale differences among the
efficiencies of the various routes suggest that the differences
may reflect the nature and density of the relevant APC
populations at various sites. Thus, Langerhans cells, assorted
subcutaneous macrophages, and peritoneal macrophages
might be involved in processing of gp96–peptide com-
plexes in the intradermal, subcutaneous, and intraperitoneal
sites, respectively. Differences in efficiencies of such APCs
have indeed been recorded (21). The primary events of
elicitation or downregulation of immune response presum-
ably occur at the level of gp96–APC interaction. Two pos-
sibilities may be envisaged. First, activation of an APC by
different quantities of gp96 may lead to qualitatively differ-
ent types of signals, one leading to stimulation of CD8
 
1
 
 T
cells and the other to generation of a downregulatory CD4
 
1
 
T cell population. This possibility, although attractive, is
weakened by the observation that stimulation of macro-
phage in vitro with gp96–peptide complexes over a wide
range of quantities leads to uniform stimulation of CD8
 
1
 
 T
cells (14). The second possibility is that a larger quantity of
gp96 molecules might interact with a larger number of
APCs, leading to generation of an amplified signal, such as
a particular cytokine or combination of cytokines, that
stimulates CD8
 
1
 
 T cells at lower levels and an inhibitory
CD4
 
1
 
 T cell population at higher levels. Presently, we fa-
vor the second possibility. It has been postulated that gp96
molecules interact with APCs through a receptor (22). In-
herent in the second possibility is the prediction that the
expression level of the putative gp96 receptor on APCs is
quite low and limiting, leading to the rather narrow win-
dow of the effective immunizing dose of gp96. Interest-
ingly, when mice are immunized with increasing doses of
irradiated, intact Meth A tumor cells ranging from 10 mil-
lion cells to 200 million cells, no restriction of immunizing
activity is observed at the higher doses (data not shown).
This result provides further support to our previous studies,
in which it was shown that the mechanisms through which
intact cells elicit immunity are distinct from the mechanism
through which gp96 isolated from the same cells becomes
immunogenic (5). The observation that immunogenicity of
gp96 is exquisitely sensitive to the abrogation of the func-
tion of APCs, whereas immunogenicity of whole cells is
not (5), further points to the APC as the site most likely to
be responsible for the dual nature of the specific immuno-
logical activity of gp96. Our results with gp96 are also rem-
iniscent of earlier studies describing high-zone tolerance
induced by immunization with large quantities of soluble
proteins (23). As gp96 molecules chaperone antigens in-
stead of being antigenic themselves (17), the differences be-
tween the mechanisms of tolerance induction in the two
instances would be interesting and instructive.
The observations that administration of several fractions
of doses is as effective in eliciting or downregulating im-
mune response as administration of a single dose appear to
suggest that both events, the immune response and its
downregulation elicited by gp96, require a threshold that
can be met by events at one microenvironment or collec-
tively at several. The observation that immunization with
several suboptimal doses can help meet the threshold to an
active immune response is understandable with relative
ease. In contrast, the observation that several immunizations,
each with an optimal immune-stimulating dose, can lead to a
systemic downregulated immune response is surprising. It
suggests that even though an immune response at a given
site may have a given consequence, it may be overridden
by independent events occurring at other sites. Collec-
tively, these results argue for a level of cross-talk among
different immunological microenvironments that appears
surprising in light of other studies that show a high degree
of autonomy for individual lymph nodes (24).
Our observations have a significant implication for ther-
apy. Autologous cancer–derived gp96 preparations have
been used for immunizing cancer patients in a pilot clinical
trial, and other such trials are underway. The quantity of
gp96 to be used in the trials requires careful calibration
such that it does not become immune inhibitory. Similar
but converse concerns must be kept in mind in considering
possible applications of the use of gp96 or other HSPs to-
ward therapy of autoimmune conditions.
Figure 5. Effect on fractionation of immunizing and downregulating
doses of gp96. Mice were immunized, as indicated, with single-site injec-
tions (1 or 5 mg i.d., each injection), or fractionated four-site (two in each
flank, so as to target the axillary and the inguinal group of lymph nodes)
injections, where the total quantity of gp96 used for immunization was
the same as used in single-site injections. All mice were challenged and
monitored as indicated in the Fig. 1 legend. 
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